Search research articles
Contact Us
Filters
Showing results (71-80 of 434) with videos related to
Page
of 44
Sort By:
Endocrine
|
April 24, 2025
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment
Miriam Longo, Maria Ida Maiorino, Dario Giugliano, et al.
Expert Opinion on Drug Discovery
|
August 15, 2014
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Mikkel Christensen, Patrick Miossec, Bjarne Due Larsen, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 21, 2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
Heidi Storgaard, Jonatan I Bagger, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 3, 2010
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
Meena Asmar, Michael Bache, Filip K Knop, et al.
BMJ Open
|
September 17, 2013
Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies
Ulrich Rohde, Nora Hedbäck, Lise L Gluud, et al.
Diabetes, Obesity & Metabolism
|
January 21, 2017
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard, Frederik Cold, Lise L Gluud, et al.
Clinical Epidemiology
|
January 22, 2024
The Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter]
Martin L Kårhus, Anne-Marie Ellegaard, Filip K Knop, et al.
Gastro Hep Advances
|
May 7, 2026
Letter to the Editor Regarding "<i>Ruminococcus gnavus</i> and Biofilm Markers in Feces From Primary Bile Acid Diarrhea Patients Indicate New Disease Mechanisms and Potential for Diagnostic Testing"
Martin L Kårhus, Dennis S Nielsen, Filip K Knop, et al.
Diabetes Care
|
April 29, 2011
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes
Jens J Holst, Filip K Knop, Tina Vilsbøll, et al.
Current Diabetes Reports
|
October 27, 2014
Glucagon and type 2 diabetes: the return of the alpha cell
Asger Lund, Jonatan I Bagger, Mikkel Christensen, et al.
Page
of 44
Search research articles
Search
Showing results (71-80 of 434) with videos related to
Sort By:
Page
of 44
Endocrine
|
April 24, 2025
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment
Miriam Longo, Maria Ida Maiorino, Dario Giugliano, et al.
Expert Opinion on Drug Discovery
|
August 15, 2014
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Mikkel Christensen, Patrick Miossec, Bjarne Due Larsen, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 21, 2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
Heidi Storgaard, Jonatan I Bagger, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 3, 2010
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
Meena Asmar, Michael Bache, Filip K Knop, et al.
BMJ Open
|
September 17, 2013
Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies
Ulrich Rohde, Nora Hedbäck, Lise L Gluud, et al.
Diabetes, Obesity & Metabolism
|
January 21, 2017
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard, Frederik Cold, Lise L Gluud, et al.
Clinical Epidemiology
|
January 22, 2024
The Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter]
Martin L Kårhus, Anne-Marie Ellegaard, Filip K Knop, et al.
Gastro Hep Advances
|
May 7, 2026
Letter to the Editor Regarding "<i>Ruminococcus gnavus</i> and Biofilm Markers in Feces From Primary Bile Acid Diarrhea Patients Indicate New Disease Mechanisms and Potential for Diagnostic Testing"
Martin L Kårhus, Dennis S Nielsen, Filip K Knop, et al.
Diabetes Care
|
April 29, 2011
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes
Jens J Holst, Filip K Knop, Tina Vilsbøll, et al.
Current Diabetes Reports
|
October 27, 2014
Glucagon and type 2 diabetes: the return of the alpha cell
Asger Lund, Jonatan I Bagger, Mikkel Christensen, et al.
Page
of 44